FAST, the Foundation for Angelman Syndrome Therapeutics, hosts annual hybrid event focused on science and pharmaceutical advancements for Angelman syndrome DOWNERS GROVE, Ill. (Dec. 15,
The first-in-human trial assessed the use of exogenous ketone formulation (KF) in individuals with Angelman syndrome DOWNERS GROVE, Ill. (December 10, 2021) — FAST, the
FAST, the Foundation for Angelman Syndrome Therapeutics, is pleased to unveil relevant behavioral assessments to measure potential change over time for investigative therapeutics for Angelman
FAST, the Foundation for Angelman Syndrome Therapeutics, is excited to accelerate their mission of bringing transformative therapeutics to all individuals living with Angelman syndrome (AS),
